Skip to main content
SpringerLink
Log in

Research Ethics and Evidence-based Medicine

  • Chapter
Evidence-based Practice in Medicine and Health Care

  • 1145 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cookson R, McDaid D, Maynard A (2001) Wrong sign, nice mess: Is national guidance distorting allocation of resources. British Medical Journal 323:743–745

    PubMed  CAS  ISI  Google Scholar 

  2. Department of Health (2002) Cost effective provision of disease modifying therapies for people with multiple sclerosis. Department of Health, London

    Google Scholar 

  3. Dillon A, Gibbs TG, Riley T, Sheldon TA (1999) The National Institute of Clinical Excellence and coverage for Relenza by the NHS. Informing judgment: Case studies of health policy and research in six countries. Milbank Memorial Fund, New York

    Google Scholar 

  4. National Institute for Clinical Excellence (2002a) Appraisal of the use of beta interferons and glatiramer acetate in the treatment of multiple sclerosis. National Institute of Clinical Excellence, London

    Google Scholar 

  5. National Institute for Clinical Excellence (2002b) Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. National institute for clinical excellence, London

    Google Scholar 

  6. National Institute for Clinical Excellence (2002c) NICE appraisal of beta interferon and glatiramer for MS. Process to 2002. National institute for clinical excellence, London

    Google Scholar 

  7. Sculpher M, Drummond M, O’Brien B (2002) Editorial. Effectiveness, efficiency and NICE. A nice start but evidence costs money. British Medical Journal 322:943–944

    ISI  Google Scholar 

  8. Smith R (2000) The failings of NICE. Time to start to work on version 2. British Medical Journal 321:1363–1364

    PubMed  CAS  ISI  Google Scholar 

Download references

Authors
  1. Reidar K. Lie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Instituut voor Gezondheidsethiek, Universiteit Maastricht, Universiteitssingel 40 (West), NL-6229, ER Maastricht, Germany

    Ruud ter Meulen

  2. Professur f. Medizinethik, Charité — Universitätsmedizin Berlin, Klingsorstrasse 119, D-12203, Berlin, Germany

    Nikola Biller-Andorno

  3. Abt. Ethik und Geschichte der Medizin, Universität Göttingen, Humboldtallee 36, D-37073, Goettingen, Germany

    Christian Lenk

  4. Department of Clinical Bioethics, National Institutes of Health, 10 Center Drive Building 10, Room 1C118, Bethesda, MD, 20892-1156, USA

    Reidar K. Lie MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lie, R.K. (2005). Research Ethics and Evidence-based Medicine. In: ter Meulen, R., Biller-Andorno, N., Lenk, C., Lie, R.K. (eds) Evidence-based Practice in Medicine and Health Care. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27133-3_11

Download citation

  • DOI: https://doi.org/10.1007/3-540-27133-3_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22239-2

  • Online ISBN: 978-3-540-27133-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation